Want to see AU:BGT full AI Analyst Report?
Top Page
Bio-Gene Technology Ltd.
(Sydney:BGT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.02
▼(-11.11% Downside)
Action:Upgraded
Date:10/28/26
The score is primarily weighed down by very weak financial performance (near-zero recent revenue, sustained losses, and ongoing cash burn). Technicals provide only modest support due to a short-term uptick that is not confirmed by longer-term trend indicators, while valuation is constrained by a negative P/E and no dividend.
Positive Factors
Low leverage
A minimally leveraged balance sheet reduces insolvency pressure and interest obligations, preserving flexibility while the company works to improve operations. Low debt can also limit refinancing exposure and leave more strategic options than a similarly unprofitable business with heavy borrowings.
Negative Factors
Near-zero revenue
Near-zero revenue means the company currently has little operating scale to support fixed costs, research activity, or commercial expansion. Without a durable recovery in sales, the business has limited evidence of customer traction and remains exposed to continued financial underperformance.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A minimally leveraged balance sheet reduces insolvency pressure and interest obligations, preserving flexibility while the company works to improve operations. Low debt can also limit refinancing exposure and leave more strategic options than a similarly unprofitable business with heavy borrowings.
Read all positive factors
Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.69M
Dividend YieldN/A
Average Volume (3M)228.06K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS Growth38.52%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding438,061,100
10 Day Avg. Volume182,529
30 Day Avg. Volume228,062
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bio-Gene Technology Ltd. Business Overview & Revenue Model
Company Description
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop pr...
Bio-Gene Technology Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
46
Neutral
Cash Flow
10
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 18.32K | 149.23K | 445.73K |
| Gross Profit | -42.00K | -245.78K | -301.45K | -164.04K | 178.59K |
| EBITDA | -3.36M | -2.58M | -2.97M | -3.14M | -2.92M |
| Net Income | -2.33M | -2.58M | -2.41M | -3.10M | -2.91M |
Balance Sheet | |||||
| Total Assets | 2.61M | 2.15M | 3.16M | 3.84M | 7.30M |
| Cash, Cash Equivalents and Short-Term Investments | 1.94M | 1.14M | 2.21M | 2.99M | 6.34M |
| Total Debt | 0.00 | 51.21K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 519.76K | 522.98K | 368.45K | 613.88K | 1.03M |
| Stockholders Equity | 2.09M | 1.63M | 2.79M | 3.22M | 6.27M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -2.54M | -2.76M | -3.28M | 36.67K |
| Operating Cash Flow | -1.94M | -2.54M | -2.75M | -3.28M | 43.52K |
| Investing Cash Flow | 0.00 | 0.00 | -5.70K | 0.00 | -6.84K |
| Financing Cash Flow | 2.74M | 1.47M | 1.98M | -75.00K | 4.41M |
Bio-Gene Technology Ltd. Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
37.15
Neutral
93.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Negative. The current price of 0.018 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 37.15 is Neutral, neither overbought nor oversold. The STOCH value of 93.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BGT.
Bio-Gene Technology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$12.36M | -1.67 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$5.69M | -1.73 | -143.11% | ― | ― | 38.52% | |
44 Neutral | AU$4.91M | 2.74 | 206.11% | ― | ― | ― | |
43 Neutral | AU$5.57M | -3.56 | -54.03% | ― | ― | -100.00% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% | |
42 Neutral | AU$30.39M | -0.34 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
AU:BGT
Bio-Gene Technology Ltd.
0.01
-0.01
-43.48%
AU:BIT
Biotron
―
―
―
AU:VBS
Vectus Biosystems Limited
0.08
-0.04
-31.30%
AU:TRP
Tissue Repair Ltd
0.10
-0.24
-71.21%
AU:CMB
Regeneus Ltd.
0.42
-0.11
-20.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.12
-91.11%
Bio-Gene Technology Ltd. Corporate Events
Bio-Gene plans issue of 6.5 million long-dated options
Oct 28, 2026
Bio-Gene Technology Ltd. has lodged a new Appendix 3B with the ASX outlining a proposed issue of securities via a placement or other type of capital raising. The company plans to issue up to 6.5 million options in a new class, exercisable at $0.03...
Bio-Gene Secures $343,000 R&D Tax Incentive to Advance Bio‑Insecticide Pipeline
Oct 19, 2026
Bio-Gene Technology Limited, an Australian developer of nature‑derived bio‑insecticides, is advancing products such as Flavocide and Qcide to combat insecticide resistance with reduced impact on human health and the environment. Its te...
Bio-Gene sets 2026 AGM date and director nomination deadline
Oct 11, 2026
Bio-Gene Technology Limited has scheduled its 2026 Annual General Meeting for Monday, 30 November 2026, and set Monday, 19 October 2026 as the deadline for shareholders or other eligible parties to submit written nominations for director positions...
Bio-Gene Details ASX Governance Compliance, Delays Gender Targets
Aug 28, 2026
Bio-Gene Technology Limited has outlined its adherence to the ASX Corporate Governance Council’s fourth-edition principles, confirming broad compliance with recommendations on board charters, director appointments, written executive agreemen...
Bio-Gene lodges updated ASX corporate governance statement and Appendix 4G
Aug 28, 2026
Bio-Gene Technology Limited has lodged its updated corporate governance statement and accompanying Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming compliance with key disclosure obligations under Listing Rules 4.7.3,...
Bio-Gene Posts Narrower 2026 Loss, Holds Asset Backing Steady
Aug 28, 2026
Bio-Gene Technology Limited has released its final report and 2026 annual report for the year ended 30 June 2026, detailing its financial and operational performance for shareholders. The company reported no revenue from ordinary activities and a ...
Bio-Gene Technology Issues 69 Million Unquoted Options
Aug 10, 2026
Bio-Gene Technology Ltd has notified the market of the issue of a large tranche of unquoted equity securities in the form of options. The company will issue 69,221,150 options, expiring on October 15, 2027, with an exercise price of A$0.035, which...
Bio-Gene Director Boosts Indirect Stake Through Share Placement and Options
Aug 10, 2026
Bio-Gene Technology Limited has reported a change in director Timothy Grogan’s indirect interests in the company’s securities via Grogan Pty Ltd, reflecting a substantial increase in his share and option holdings. Following a recent tr...
Bio-Gene Raises A$3.3m Through Completed Share Placement and Option Issue
Aug 10, 2026
Bio-Gene Technology Limited has completed the second tranche of a share placement and associated share purchase plan underwriting, issuing 51,980,000 fully paid shares following shareholder approval at its recent extraordinary general meeting. The...
Bio-Gene Technology Seeks ASX Quotation for 15.2 Million New Shares
Aug 10, 2026
Bio-Gene Technology Ltd., an ASX-listed biotechnology company trading under the code BGT, develops and commercialises biological technologies with a focus on innovative solutions for the life sciences and related markets.The company has applied fo...
Bio-Gene Seeks ASX Quotation for 34.8 Million New Shares
Aug 10, 2026
Bio-Gene Technology Ltd., an ASX-listed biotechnology firm, has moved to expand its listed equity base with a new batch of ordinary fully paid shares. The company’s securities, identified under the BGT ticker, continue to form the foundation...
Bio-Gene Technology Seeks Quotation for 2 Million New ASX Shares
Aug 10, 2026
Bio-Gene Technology has lodged a new application with the ASX for quotation of additional ordinary fully paid shares. The company is seeking quotation for 2,000,000 BGT securities, reflecting a modest expansion of its listed equity base.The new se...
Bio-Gene Wins Shareholder Backing for Capital Plans at Extraordinary Meeting
Aug 5, 2026
Bio-Gene Technology Limited is an Australian agritech company developing novel bio-insecticides to address insecticide resistance and the demand for natural pest control solutions. Its products, including proprietary brands Flavocide and Qcide, ar...
Bio-Gene advances Asian vector control push and Japan launch plans for Qcide
Jul 31, 2026
Bio-Gene has expanded evaluation of its Flavocide and Qcide mosquito control technologies into Asia, with WHO-aligned testing in Singapore and the wider region targeting key disease-carrying species such as Aedes aegypti and Aedes albopictus. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.